Biodegradable Bone Graft Extender

Information

  • Research Project
  • 6337336
  • ApplicationId
    6337336
  • Core Project Number
    R43AR046970
  • Full Project Number
    1R43AR046970-01A1
  • Serial Number
    46970
  • FOA Number
  • Sub Project Id
  • Project Start Date
    5/1/2001 - 23 years ago
  • Project End Date
    10/31/2001 - 22 years ago
  • Program Officer Name
    PANAGIS, JAMES S.
  • Budget Start Date
    5/1/2001 - 23 years ago
  • Budget End Date
    10/31/2001 - 22 years ago
  • Fiscal Year
    2001
  • Support Year
    1
  • Suffix
    A1
  • Award Notice Date
    4/19/2001 - 23 years ago

Biodegradable Bone Graft Extender

DESCRIPTION (Verbatim From Applicant): In order to expand the clinical utility of bone replacement materials, we are proposing to develop a biodegradable bone graft extender with inductive capacity. Inductive biodegradable extenders would be useful in situations where autografts are preferable, yet the patients own bone stocks are insufficient. This SBIR Phase I project will determine the feasibility of enhancing the regeneration of skeletal tissues with an extender fashioned from the biopolymer poly(propylene glycol-co-fumaric acid) (PPF). This unsaturated polymer can be crosslinked in the presence of effervescent agents to create an osteoconductive network that can be immediately mixed with autograft prior to defect filling. In Phase I we will seek to develop polymer/bone combinations that demonstrate in vitro and in vivo durability over time, while supporting bone formation equivalent to traditional autologous bone grafting. Phase II would then address research objectives directed towards resolution of the clinical dilemma where autologous bone graft is recognized as the preferable "gold standard," but may not be available in sufficient quantities. This composite could have biological properties that are superior to the cortico-cancellous allogeneic bone chips routinely used in this situation. Osteoinductive autograft material used in conjunction with a highly osteoconductive, yet resorbable, scaffold would be attractive for both induction and expansion of new bone formation. PROPOSED COMMERCIAL APPLICATION: Bone grafts are used in over 425,000 musculoskeletal operations annually. Overall, 80% of the bone grafts are used in orthopaedic and spine surgery. Autografts are the preferred grafting material, but sometimes the patient's own bone stocks are deficient. It is estimated that synthetic bone replacement materials are used in only 25,000 - 35,000 of clinical grafting procedures because they are primarily only osteoconductive. If autogenous grafts could be easily extended via a resorbable osteoconductive material, market acceptance would follow.

IC Name
NATIONAL INSTITUTE OF ARTHRITIS AND MUSCULOSKELETAL AND SKIN DISEASES
  • Activity
    R43
  • Administering IC
    AR
  • Application Type
    1
  • Direct Cost Amount
  • Indirect Cost Amount
  • Total Cost
    99999
  • Sub Project Total Cost
  • ARRA Funded
  • CFDA Code
    846
  • Ed Inst. Type
  • Funding ICs
    NIAMS:99999\
  • Funding Mechanism
  • Study Section
    ZRG1
  • Study Section Name
    Special Emphasis Panel
  • Organization Name
    CAMBRIDGE SCIENTIFIC, INC.
  • Organization Department
  • Organization DUNS
  • Organization City
    CAMBRIDGE
  • Organization State
    MA
  • Organization Country
    UNITED STATES
  • Organization Zip Code
    02138
  • Organization District
    UNITED STATES